Our mission is to accelerate the development of stem cell research and treatments. We therefore sponsor and support clinical trials internationally.
Current Clinical Trials
Cellcolabs' cells are used in international clinical trials for a number of conditions, including Ageing Frailty, Osteoarthritis (OA), Musculoskeletal Injuries and prevention of various diseases.
As with most other stem cell products, Cellcolabs´ stem cells are classified as an investigational medicinal product (iATMP) and do not yet have market approval. Although research has shown promising clinical outcomes, the underlying mechanism of stem cell treatment has not yet been explicated. As such, clinical trials are necessary to provide more research and data. Cellcolabs supports this work through driving scale in both academic research and our own clinical trials.
If you are interested in joining a clinical trial, visit clinical.cellcolabs.com for more information.
Realizing the potential
Studies have shown that mesenchymal stromal cells (MSCs) reduce inflammation, modulate the immune system, and regenerate damaged or diseased tissues. These properties make MSCs a promising candidate to address a number of chronic diseases whose current treatment methods are insufficient, to accelerate better health and quality of life globally.
Cellcolabs was founded in response to the poor availability and high prices of high-quality stem cells for research and treatments. The high quality of our stem cells is ensured through our production protocol, which is the result of over 20 years of research at the Karolinska Institute in Sweden, including 167 published scientific papers with over 30,000 citations (as of 2021). Furthermore, our MSCs are produced from the bone marrow of rigorously screened, healthy, young donors, to ensure maximal potency.
Our Clinical Partners
Our Stem Cells
Connect with us!
If you would like to learn more about our clinical trials, please fill out the form below or email firstname.lastname@example.org and we will be in touch. We will do our best to answer your questions.
Autologous stem cell treatments use cells derived form the patient's own body. In practice, this often involves extracting MSCs from the fat tissue and injecting the patient with a concentrate including stem cells from the fat. This treatment option is widespread today since it is not classified as a medicinal product. This however also means that there is no control from medical authorities such as EMA and FDA.
Allogeneic stem cell treatments use the cells obtained from a donor. Cellcolabs' cells are harvested from the bone marrow of healthy donors 18-28 years old, and cultivated in our production facility at the Karolinska Institute Campus in Stockholm.There are various advantages with allogeneic MSC treatments produced by companies that follow the EU or US regulations. The quality is strictly regulated and controlled, meaning that we can be certain that the patient receives the intended amount and potency of cells. There is data indicating that MSCs from younger people are more potent than from older ones, which is why Cellcolabs' donors are young and rigorously screened. One donor can provide enough cells to more than 100 patients, and the cells are cryopreserved and readily available "off-the-shelf", enabling a comfortable experience for the patient and fast turnaround times for the healthcare system.